365 related articles for article (PubMed ID: 21684855)
1. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
[TBL] [Abstract][Full Text] [Related]
2. Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.
Pérez-Elías MJ; Gatell JM; Flores J; Santos J; Vera-Médez F; Clotet B; Moreno A; Pérez-Molina JA; Vendrell B; Serrano O
HIV Clin Trials; 2009; 10(4):269-75. PubMed ID: 19723614
[TBL] [Abstract][Full Text] [Related]
3. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
[TBL] [Abstract][Full Text] [Related]
4. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
5. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
[TBL] [Abstract][Full Text] [Related]
6. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
[TBL] [Abstract][Full Text] [Related]
7. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
[TBL] [Abstract][Full Text] [Related]
8. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
10. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Sutherland-Phillips DH; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
HIV Clin Trials; 2010; 11(2):69-79. PubMed ID: 20542844
[TBL] [Abstract][Full Text] [Related]
12. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D
Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732
[TBL] [Abstract][Full Text] [Related]
14. Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.
Rubio R; Serrano O; Carmena J; Asensi V; Echevarría S; Flores J; Ribera E; Zarraga M; Ocampo A; de la Fuente B; Sepúlveda MA; Mariño AI; Minguez C; Vicent R; Cartón JA; Moyano B; Esteban H; Mahillo B; Serrano L; González-García J;
HIV Med; 2010 Oct; 11(9):545-53. PubMed ID: 20345884
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
16. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team
HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.
Malan DR; Krantz E; David N; Wirtz V; Hammond J; McGrath D;
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):161-7. PubMed ID: 17971713
[TBL] [Abstract][Full Text] [Related]
18. Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.
Elion R; Dejesus E; Sension M; Berger D; Towner W; Richmond G; St Clair M; Yau L; Ha B;
HIV Clin Trials; 2008; 9(3):152-63. PubMed ID: 18547902
[TBL] [Abstract][Full Text] [Related]
19. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
[TBL] [Abstract][Full Text] [Related]
20. Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.
Castagna A; Spagnuolo V; Galli L; Vinci C; Nozza S; Carini E; D'Arminio Monforte A; Montella F; Antinori A; Di Biagio A; Rusconi S; Lazzarin A;
AIDS; 2014 Sep; 28(15):2269-79. PubMed ID: 25058680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]